Literature DB >> 557953

Relationship between the physicochemical nature of human interferon, the cell induced, and the inducing agent.

T C Cesario, P J Schryer, J G Tilles.   

Abstract

To determine the basis for differences in interferons previously noted by others, we prepared five types of human interferon, namely interferon induced in muscle skin fibroblasts using complexed polyinosinic:polycytidylic acid (IC) and Newcastle disease virus (NDV), and interferon induced in leukocytes using IC, NDV, and phytohemagglutinin. We determined the molecular weight, isoelectric point, inactivation rate at 56 degrees C and structural activity relationships for each interferon. Significant differences between these interferons were found, many of which seem related to the cell induced rather than the inducer. We believe these findings have important pharmacological implications for the use of interferon in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 557953      PMCID: PMC351970          DOI: 10.1128/AAC.11.2.291

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  SOME SIMILARITIES BETWEEN A VIRAL INHIBITOR OF PLANT ORIGIN AND CHICK INTERFERON.

Authors:  K H FANTES; C F O'NEILL
Journal:  Nature       Date:  1964-09-05       Impact factor: 49.962

2.  Stability of human leukocyte interferon towards heat.

Authors:  K E Mogensen; K Cantell
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-06

3.  Inactivation of human interferon by urine.

Authors:  T Cesario; J G Tilles
Journal:  J Infect Dis       Date:  1973-03       Impact factor: 5.226

4.  Studies on the physico-chemical inactivation of rabbit inerferons.

Authors:  Y H Ke; M Ho
Journal:  Proc Soc Exp Biol Med       Date:  1968-11

5.  [Comparative study of the molecular weights of 2 human interferons produced in vitro].

Authors:  E Falcoff; F Fournier; C Chany
Journal:  Ann Inst Pasteur (Paris)       Date:  1966-09

6.  Isoelectric components of mouse, human, and rabbit interferons.

Authors:  D Stancek; M Gressnerová; K Paucker
Journal:  Virology       Date:  1970-08       Impact factor: 3.616

7.  Inactivation of interferon: the effect of protonation.

Authors:  L W Marshall; P M Pitha; W A Carter
Journal:  Virology       Date:  1972-05       Impact factor: 3.616

8.  Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons.

Authors:  M J Valle; G W Jordan; S Haahr; T C Merigan
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

9.  Two antigenically distinct species of human interferon.

Authors:  E A Havell; B Berman; C A Ogburn; K Berg; K Paucker; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

10.  Estimation of the molecular weights of proteins by Sephadex gel-filtration.

Authors:  P Andrews
Journal:  Biochem J       Date:  1964-05       Impact factor: 3.766

View more
  5 in total

1.  Elimination of size and charge heterogeneities of human leukocyte interferons by chemical cleavage.

Authors:  W E Stewart; L S Lin; M Wiranowska-Stewart; K Cantell
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

2.  Diminished antiviral effect of human interferon in the presence of therapeutic concentrations of antineoplastic agents.

Authors:  T C Cesario; L M Slater
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

3.  Enzymatic modifications of human fibroblast and leukocyte interferons.

Authors:  M J Otto; J J Sedmak; S E Grossberg
Journal:  J Virol       Date:  1980-08       Impact factor: 5.103

Review 4.  Differences between human alpha (leukocyte) and beta (fibroblast) interferons.

Authors:  T G Hayes
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

5.  Inactivators of fibroblast interferon found in human serum.

Authors:  T Cesario; N Vaziri; L Slater; J Tilles
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.